Register Now: Hear from AliveCor's founder, Dr David, on his personal journey, the genesis of AliveCor, and his vision for the future of cardiology

AliveCor Logo

Our Products

KardiaMobile 6L
InstantQT
KardiaPro
Kardia ECG Devices

Our Solutions

AF Screening
Data Integration Solutions
Healthcare Providers
BioPharma

About

Leadership
Mission
Clinical Research
Newsroom
Shop all Products
Resource Hub
Contact Us
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • Mission
    • Leadership
    • Research
    • Careers
    • Newsroom
    • Resource Hub
    • FAQs
    • User Manuals
    • Shipping
    • Warranty
    • Resellers
    • Integration
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
    • Modern Slavery Statement
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Go Back
AliveCor Raises $10.5M in Series B Financing
SAN FRANCISCO Calif., 11 June 2012

Capital to Fund Commercialization and Global Expansion of Breakthrough mHealth Devices

AliveCor, Inc. announced today that it raised $10.5 million in Series B venture financing. The financing comes on the heels of recent presentations at major cardiology conferences, in which supporting data demonstrated the clinical utility and accuracy of AliveCor’s device in monitoring patients’ heart health.

Existing investor Burrill & Company and new investor, Khosla Ventures, led the financing along with participation from Series A investors, Qualcomm Incorporated, through its Qualcomm Ventures investment arm and Qualcomm Life Fund, and the Oklahoma Life Sciences Fund. AliveCor will use the funding to launch and commercialize its mobile ECG device, pending 510(k) marketing clearance by the Food and Drug Administration, in the human health and animal health markets. The funding also enables expansion for new mHealth applications and services for international markets. In addition, the company announced that Michael Kourey, an operating partner at Khosla Ventures and former Polycom CFO and Board member, would immediately join AliveCor’s Board of Directors.

“This funding provides us with the resources to support the global launch of our highly anticipated iOS and Android ECG devices, and to utilize our transformative technology and data to strategically build future devices and services,” commented Judy Wade, AliveCor’s President, CEO and Director. “This round of financing, along with the support and expertise of the Board, will allow us to further realize our vision of providing mobile devices to identify, prevent and manage life-altering diseases.”

“AliveCor’s unique innovation offers the ability to decrease the cost and increase the global availability of advanced cardiac monitoring,” said G. Steven Burrill, CEO of Burrill & Company, which has made a strong commitment to funding breakthrough digital and wireless health technologies that fundamentally improve healthcare access and quality. “Heart health remains a huge cost to the healthcare system. Burrill & Company is pleased to be a part of this round and AliveCor’s exciting next stage of development.”

Let's transform cardiovascular care together

If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.